AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Isofol Medical

Major Shareholding Notification Oct 13, 2022

3063_iss_2022-10-13_3ef8ed84-0e76-4d11-9e84-c136e2877cd4.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Issuer Isofol Medical AB (publ)

Holder

Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension

Instrument

Instrument Aktier
Before the transaction
Shares Data not given*
Voting rights Data not given*
Transaction
Reason for major shareholding notification Share loan
Date 12/10/2022
Limit for number of shares 5 %
Limit for number of votes 5 %
After the transaction
Quantity
Shares 4,987,571
Directly held voting rights 0
Indirectly held voting rights 4,987,571
Percentage
Directly held shares 3.08798 %
Directly held voting rights 0 %
Indirectly held voting rights 3.08798 %

Resulting distribution of total holdings

Percentage of voting
rights:
Number of underlying
shares:
Shares 3.08798 % 4,987,571
Instruments - FITA Ch. 4, section 2, first
paragraph, line 2
Instruments - FITA Ch. 4, section 2,
first paragraph, line 3
- Physically settled
- Cash settled 2.96078 % 4,782,124
Total 6.04876 % 9,769,695

Group total holdings

Voting rights 9,769,695 Percentage of voting rights 6.04877

Notes (other relevant informations according to law)

Aktierna, samt övriga instrument enligt LHF 4 kap, 2§ första stycket 1 och finansiella instrument enligt LHF 4 kap. 2§ första stycket 3 innehas av Försäkringsaktiebolaget Avanza Pension som är ett helägt dotterbolag till Avanza Bank Holding AB (publ). Angivet gränsvärde har underskridits på grund av utlåning av aktier.

Published

13/10/2022 10:37

Contact

Name Marie Andersson

Email [email protected]

*Source of information has chosen not to submit the data

CLOSE PRINT

[email protected] Tfn 08-408 980 37 Fax 08-24 39 25

Talk to a Data Expert

Have a question? We'll get back to you promptly.